Clinical assessment of 5-fluorouracil/leucovorin, nab-paclitaxel, and irinotecan (folfirabrax) in untreated patients with gastrointestinal cancer using UGT1A1 genotype–guided dosing

Smita S. Joshi, Daniel V.T. Catenacci, Theodore G. Karrison, Jaclyn D. Peterson, Mark M. Zalupski, Amikar Sehdev, James Wade, Ahad Sadiq, Vincent J. Picozzi, Andrea Amico, Robert Marsh, Mark F. Kozloff, Blase N. Polite, Hedy L. Kindler, Manish R. Sharma*

*Corresponding author for this work

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Clinical assessment of 5-fluorouracil/leucovorin, nab-paclitaxel, and irinotecan (folfirabrax) in untreated patients with gastrointestinal cancer using UGT1A1 genotype–guided dosing'. Together they form a unique fingerprint.

Medicine & Life Sciences